US Prevalence
~30,000
Americans living with HD; ~200,000 at risk. Small numbers, enormous family impact from autosomal dominant inheritance.[1]
What Is It
Definition, mechanism, and the clinical reality of Huntington's disease at end of life. What the hospice team needs to understand on day one.
CAG Repeat Threshold
≥40
CAG repeats in HTT gene = full penetrance HD. 36–39 = reduced penetrance. >60 = juvenile onset. Higher repeats = earlier onset.[2]
Psychiatric Prevalence
40–70%
Of HD patients develop major depression. ~10% develop psychosis. Psychiatric symptoms often predate motor symptoms by years.[3]
Aspiration Death
65–70%
Of HD deaths are from aspiration pneumonia — progressive chorea-impaired swallowing and dysphagia define the terminal trajectory.[4]
Huntington's disease is the progressive degeneration of medium spiny neurons in the striatum — the brain region responsible for movement coordination, cognition, and behavioral regulation. The mutation is a CAG trinucleotide repeat expansion in the HTT gene on chromosome 4: longer expansions cause earlier onset and faster progression. What emerges is a triad of motor, cognitive, and psychiatric deterioration that is inseparable and mutually amplifying. There is no disease-modifying treatment. There is no cure. Every intervention is symptomatic.[1][2]
End-stage HD is defined by the convergence of severe chorea that exhausts caloric reserves despite constant involuntary movement, dysphagia that makes every meal a potential aspiration event, cognitive decline that progressively impairs the patient's ability to participate in their own care, and a psychiatric landscape of depression, anxiety, irritability, and sometimes psychosis that has often been present for years before any motor symptom appeared. What makes HD uniquely devastating in hospice is the certainty: the patient knew this was coming — perhaps since childhood, watching a parent — and every child in the family faces a 50% risk of carrying the same mutation.[5]
🧭 Clinical framing
The hospice clinician who walks into a Huntington's home is not just caring for a dying person. They are caring for a family living under the weight of a genetic inheritance that may already be present — and as yet undiagnosed — in the adult children sitting beside the bed. Every clinical decision, every conversation about prognosis, every family meeting happens in the context of a disease that is autosomal dominant, 100% penetrant above 40 CAG repeats, and entirely without a cure. The patient was born with this mutation. The parent who gave it to them may have died of it already. The children may carry it. You are walking into three generations of grief.[6]
"The first time you walk into an HD home, look at who's in the room. The adult daughter helping with the feeding — she may have been tested. She may know she carries the gene. She may be watching her own future. Every visit in an HD home is a visit with the whole family's mortality, not just the patient's."
— Waldo, NP · Terminal2
How It's Diagnosed
Genetic testing, neurological examination, and what to look for in hospice records. Most HD patients arrive with an established genetic diagnosis — this section helps you read it.
Genetic Testing — The Definitive Diagnosis
- PCR amplification of CAG repeat number in the HTT gene on chromosome 4p16.3
- ≥40 CAG repeats: Full penetrance — HD will develop if patient lives long enough
- 36–39 repeats: Reduced penetrance — may or may not develop HD
- 27–35 repeats: Intermediate — will not develop HD but may expand in next generation
- <27 repeats: Normal range — no HD risk
- Predictive testing: Available for at-risk individuals before symptom onset; ~20–25% of at-risk individuals choose testing; requires formal genetic counseling per HDSA guidelines[7]
What to Look for in Hospice Records
- CAG repeat number: Higher repeats = earlier onset and faster progression; >60 = juvenile HD
- UHDRS Total Functional Capacity (TFC): 0–13 scale; TFC ≤3 = Stage IV–V; TFC 0 = total dependence[8]
- MRI brain: Progressive caudate atrophy — pathognomonic finding; ventricular enlargement; cortical atrophy in later stages
- CYP2D6 genotype: Required for tetrabenazine doses >50 mg/day — review prior testing
- Psychiatric history: Depression treatment, suicidality episodes, antipsychotic use, hospitalizations
- Current VMAT2 inhibitor: Tetrabenazine or deutetrabenazine dose, tolerability, last depression screen
Neurological Examination
- Chorea: Involuntary, dance-like, flowing movements of extremities and trunk — the cardinal motor sign
- Dystonia: Sustained muscle contractions causing abnormal postures — increasingly dominant in late-stage
- Bradykinesia: Slowed voluntary movement — often replaces chorea in end-stage HD
- Rigidity: Frequently replaces chorea in terminal phase — a critical clinical transition point
- Oculomotor abnormalities: Slowed saccades, difficulty initiating voluntary eye movements[9]
- Dysarthria and dysphagia: Progressive — assess at every visit
- Gait: Wide-based, choreiform — high fall risk
Cognitive & Psychiatric Assessment
- HD cognitive profile: Executive dysfunction (planning, set-shifting, working memory), slowed processing speed, memory retrieval difficulties with relatively preserved recognition, visuospatial impairment[10]
- UHDRS cognitive battery: Symbol digit modalities test, Stroop, verbal fluency
- MoCA: General screening tool — useful for serial tracking
- PHQ-9: Depression screening — depression in HD is biological, not reactive; affects 40–70%[3]
- Behavioral assessment: Irritability, apathy (distinct from depression), obsessive-compulsive behaviors, psychosis (~10%)
💡 For families
Your loved one's HD diagnosis was confirmed through a genetic blood test that measures a specific DNA sequence. This test is definitive — there is no uncertainty about the diagnosis. At hospice enrollment, all diagnostic workup is complete. The focus now is entirely on comfort, symptom management, and supporting your family through this journey.
Causes & Risk Factors
Genetics is the entirety of HD causation. There are no environmental, behavioral, or lifestyle risk factors. No one chooses or causes Huntington's disease.
The Genetic Cause — HTT Gene
- Autosomal dominant: Each child of an affected parent has a 50% chance of inheriting the mutation[2]
- CAG trinucleotide repeat expansion: In the HTT gene on chromosome 4p16.3 — the expanded protein (mutant huntingtin) is toxic to striatal neurons
- Full penetrance at ≥40 repeats: The disease will develop if the person lives long enough
- De novo mutations are extremely rare: ~3% of cases from intermediate allele expansion in parental generation
Inheritance & Anticipation
- CAG repeat instability: The repeat can expand during transmission — especially through paternal inheritance[11]
- Anticipation: Children may have longer repeat lengths than their affected parent, causing earlier onset in the next generation
- Juvenile HD (<20 years onset): CAG >60 repeats; presents with rigidity and bradykinesia (Westphal variant); epilepsy more common; faster progression
- ~200,000 Americans at risk: ~75–80% of at-risk individuals choose not to be tested — living with profound uncertainty[7]
❤️ For families: "Why did this happen?"
Huntington's disease is caused entirely by a genetic mutation that was inherited. It was not caused by anything your loved one did, ate, breathed, or chose. There are no lifestyle risk factors. There are no environmental triggers. This is a genetic disease passed from parent to child, and no one is at fault. If you carry guilt about this, put it down. Biology does not assign blame.[2]
⚕ Clinician note: Genetic counseling
Even at hospice enrollment, the genetic reality of HD demands attention. The patient's adult children have a 50% risk. Some may have been tested; some have not. Genetic counseling referral for at-risk family members is appropriate at any time — including during the patient's hospice course. The HDSA requires comprehensive pre-test and post-test genetic counseling. Do not assume that family genetic conversations have happened — ask explicitly.[7]
Treatments & Procedures
No disease-modifying therapy exists for HD. All treatment is symptomatic. Understanding the medications this patient is on — and why — is essential for hospice management.
There is no disease-modifying therapy for Huntington's disease. This is the defining clinical reality of HD hospice care. Antisense oligonucleotides targeting HTT mRNA (tominersen) had Phase III trials stopped for safety signals. Gene-silencing approaches continue in development but none are approved. Every medication this patient takes is symptomatic — managing chorea, depression, psychosis, sleep, pain, or nutrition. The clinical skill is in optimizing the symphony of symptomatic medications while anticipating the progressive loss of oral intake that will eventually compromise medication delivery.[12]
Chorea Management
- Tetrabenazine (Xenazine): VMAT2 inhibitor; FDA-approved for HD chorea; effective but significant side effects: depression, sedation, parkinsonism, suicidality; requires CYP2D6 genotyping for doses >50 mg/day[13]
- Deutetrabenazine (Austedo): Deuterated tetrabenazine; longer half-life; better tolerated; FDA-approved; preferred over tetrabenazine for most patients[14]
- Antipsychotics (quetiapine, olanzapine): Reduce chorea via D2 blockade; also treat psychiatric symptoms; quetiapine preferred in HD for dual benefit
- Benzodiazepines (clonazepam): Reduce chorea and anxiety simultaneously; useful in end-stage HD comfort-focused care
Palliative Procedures & Supportive
- PEG tube placement: For medication delivery and nutritional support when oral intake is insufficient — earlier discussion in HD than in other diagnoses because cognitive decline may close the informed consent window[15]
- SLP swallowing assessment: Modified barium swallow; texture modification; compensatory swallowing strategies; reassessment with progression
- Dietitian consultation: Critical at enrollment — HD caloric requirements are extraordinary (5,000–6,000 kcal/day in severe chorea)
- Physical therapy: Fall prevention, positioning, wheelchair optimization, pressure injury prevention
When Therapy Makes Sense
In HD, "therapy" means symptom management. These are the clinical situations where active pharmacological intervention continues to serve comfort goals.
In Huntington's disease, unlike cancer, there is no disease-directed therapy to continue or discontinue. The question is not "should we treat?" but "which symptomatic treatments serve this patient's comfort at this stage?" Every medication is evaluated against current symptom burden, not disease progression.[16]
- 01VMAT2 inhibitor for distressing chorea: Chorea that causes falls, prevents comfortable positioning, disrupts sleep, or is experienced as distressing by the patient deserves pharmacological management. This is a comfort intervention. Continue deutetrabenazine or tetrabenazine when chorea is the dominant comfort problem.[14]
- 02Antidepressant continuation or initiation: Depression in HD is biological and requires pharmacological treatment at any stage. Even in end-stage cognitively impaired HD, behavioral signs of depression (weeping, agitation, withdrawal from food) should trigger antidepressant use. Mirtazapine is ideal — combines antidepressant effect with appetite stimulation and sleep benefit.[17]
- 03Quetiapine for concurrent psychiatric symptoms and chorea: The antipsychotic that simultaneously manages chorea, irritability, psychosis, and sleep. Reduces caregiver burden and patient distress. Preferred over typical antipsychotics which worsen motor symptoms in HD.[18]
- 04Modified texture diet and SLP management: Even in comfort-focused goals, optimizing swallowing safety and eating pleasure extends quality of life and reduces aspiration frequency. A dietitian and SLP at enrollment is standard of care in HD hospice.
- 05PEG for medication delivery and nutritional support: Earlier PEG discussion in HD than other diagnoses — cognitive decline may close the informed consent window. When oral intake is insufficient and the patient or surrogate wishes to continue nutrition, PEG serves comfort goals.[15]
When It Doesn't
Knowing when symptomatic treatment adds burden rather than comfort is the defining clinical skill in end-stage HD management.
Every medication in HD must be reassessed against its benefit-burden ratio as the disease progresses. The medication that was essential at UHDRS Stage III may be causing harm at Stage V. The clinical skill is in recognizing the transition points and deprescribing explicitly.[16]
- 01VMAT2 inhibitors causing depression, suicidality, or severe sedation: The medication that treats chorea but causes the patient to become severely depressed or immobile has crossed the benefit-burden threshold. Reduce or stop. Chorea in the final stages often diminishes spontaneously as rigidity and bradykinesia become dominant — reassess indication at every visit.[13]
- 02Antipsychotics causing severe sedation or worsening swallowing: Any medication that worsens swallowing in an already dysphagia-dependent patient is potentially hastening death from aspiration. Reassess all psychotropic medications against their swallowing safety profile in advanced HD.[19]
- 03Tube feeding in advanced HD dementia when the goal is aspiration prevention: PEG does not prevent aspiration pneumonia in advanced HD dementia — the same evidence applies as in other neurodegenerative dementias. If the explicit goal is aspiration prevention, the evidence does not support it. If the goal is medication delivery and selected nutrition, the conversation is different.[20]
- 04Complex medication regimens requiring monitoring in the actively dying patient: Mirtazapine and SSRIs can continue. MAOIs and complex regimens requiring laboratory monitoring should be simplified. Tetrabenazine requiring CYP2D6 monitoring and dose titration may be replaced by simpler alternatives.
- 05High-calorie supplementation when swallowing is unsafe and PEG is declined: The patient whose dysphagia is complete and who has declined PEG does not benefit from continued attempts at oral high-calorie intake. The goal shifts to comfort oral pleasure in whatever safe form remains — ice chips, mouth swabs, small tastes of preferred foods.
📋 The suicidality conversation
HD carries a lifetime suicide risk of 5–10%, with the highest risk in the premanifest and early manifest stages when cognitive function is preserved and the patient has full awareness of what is coming. At hospice enrollment, the cognitively intact HD patient requires active suicidality assessment at every visit. This is not adequately managed by the antidepressant prescription alone — it requires direct questioning, documentation, and immediate escalation if active ideation is present.[21]
Out-of-the-Box Approaches
Evidence-graded integrative and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical; D = expert opinion.
Mirtazapine — Triple-Benefit Antidepressant
Grade B15–30 mg PO/PEG at bedtime
Mirtazapine provides triple benefit in end-stage HD: antidepressant effect via NaSSA mechanism, appetite stimulation via histamine H1 antagonism (critical in the hypercatabolic HD patient losing weight), and sedating effect for the near-universal sleep disruption. The ideal single antidepressant choice in end-stage HD when weight loss and sleep disruption accompany depression. Prescribe at every enrollment where depression and weight loss co-exist.[17]
Quetiapine — Multi-Domain Antipsychotic
Grade B25–100 mg BID-TID
Quetiapine addresses multiple HD symptom domains simultaneously: reduces chorea via D2 blockade, treats irritability, aggression, and psychosis, reduces anxiety, and at low doses aids sleep. Avoids the motor-worsening effects of typical antipsychotics. Preferred over haloperidol or risperidone which must never be used in HD — they worsen motor symptoms and have been associated with severe adverse reactions.[18]
Aggressive Caloric Management
Grade B5,000–6,000 kcal/day in severe chorea; high-calorie supplements between meals
The continuous involuntary movement of chorea creates a metabolic demand that rivals marathon running. HD patients may require 5,000–6,000 kcal/day. Weight maintenance is a primary quality-of-life indicator and a direct survival predictor in HD. High-calorie supplements (Ensure Plus, Boost Very High Calorie, Scandishake), enriched food preparation, and eating in the position of optimal swallowing safety are all comfort interventions. A dietitian consultation at enrollment is a clinical priority.[22]
Music Therapy for HD Behavioral Symptoms
Grade C30–60 min structured sessions; 2–3×/week; familiar music preferred
Music therapy reduces agitation, improves mood, and may temporarily reduce chorea amplitude in HD patients. Emotional and musical memory are preserved longer than cognitive function in HD — patients who cannot speak may still sing. Familiar music from the patient's biography is most effective. Low risk, high comfort value. Consider at every enrollment.[23]
Weighted Blankets & Sensory Modulation
Grade D10–15 lb weighted blanket during rest; adaptive utensils for meals
Weighted blankets may reduce chorea amplitude during rest and improve sleep onset. Deep pressure stimulation is the proposed mechanism. No HD-specific RCTs but widely used in movement disorder clinics with anecdotal benefit. Adaptive utensils, plate guards, and non-spill cups improve feeding independence and reduce mealtime frustration. Low risk, high dignity value.
Voice Banking & Communication Technology
Grade DInitiate while speech is intelligible; AAC device introduction before crisis
Voice banking (recording the patient's voice while still intelligible for later text-to-speech use) preserves identity and dignity. Augmentative and alternative communication (AAC) devices should be introduced before dysarthria renders speech unintelligible. This is a legacy and comfort intervention — the patient who can still communicate through technology after losing speech retains agency and connection.[24]
Natural & Herbal Options
Evidence grading, dosing, drug interaction flags, and contraindications specific to Huntington's disease. The VMAT2 inhibitor interaction profile defines the safety landscape.
"HD creates a supplement environment defined by two competing clinical priorities: the extraordinary caloric demand from chorea that makes any calorie-contributing supplement potentially beneficial, and the psychiatric fragility — depression, suicidality, irritability — that makes any supplement affecting serotonin, dopamine, or CNS stimulation potentially dangerous. If it affects dopamine or serotonin pathways, verify the interaction with the VMAT2 inhibitor before recommending."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Coenzyme Q10 | Grade C | 100–200 mg daily | Mitochondrial support; safe and well-tolerated in HD; Phase III 2CARE trial showed no clinical benefit at high doses but no harm[25] | No VMAT2 interaction. PEG-compatible. Reasonable to continue if already taking. Do not initiate as therapeutic agent — no evidence of benefit. |
| Omega-3 / DHA | Grade C | 1 g/day EPA+DHA | Neuroprotective mechanisms in striatal disease; some observational HD data; anti-inflammatory | Antiplatelet effect — caution if anticoagulated. No VMAT2 interaction. PEG-compatible. Safe in HD at standard doses. |
| High-Calorie Supplements | Grade B | Scandishake 440 kcal/serving; Ensure Plus 350 kcal; Boost VHC | Critical nutritional intervention in HD — caloric supplementation is a medical priority in chorea-driven weight loss[22] | Administer via PEG if swallowing unsafe for liquids. These are comfort nutrition interventions, not optional supplements. |
| Melatonin | Grade C | 3–10 mg at bedtime | Sleep disruption is near-universal in HD from chorea during sleep, circadian rhythm disruption, and psychiatric comorbidity | No VMAT2 interaction. No dopaminergic or serotonergic activity. Safe and well-tolerated. Use alongside sleep hygiene measures.[26] |
| Creatine Monohydrate | Grade C | 5–10 g daily | Energy metabolism support in HD; CREST-E trial showed no benefit at high doses but safe; may support muscle energy in cachectic patients | No VMAT2 interaction. PEG-compatible. Adequate hydration needed. Do not recommend as disease-modifying — use for weight and energy support only.[27] |
| Vitamin D3 | Grade C | 2,000–4,000 IU daily | HD patients are frequently deficient from immobility and limited sun exposure; bone health in fall-risk population | No VMAT2 interaction. PEG-compatible. Monitor calcium if on high doses. Standard supplementation — not HD-specific but important. |
🚫 Avoid in Huntington's Disease
- St. John's Wort: CYP inducer — reduces tetrabenazine and deutetrabenazine levels; serotonergic activity risks serotonin syndrome with concurrent SSRIs; contraindicated in HD patients on VMAT2 inhibitors or antidepressants[28]
- 5-HTP / L-Tryptophan: Serotonin precursors — risk of serotonin syndrome with SSRIs and mirtazapine; may worsen chorea via serotonergic mechanisms; contraindicated
- Kava: Dopaminergic activity may worsen psychiatric symptoms or interfere with VMAT2 inhibitor mechanism; hepatotoxicity risk; avoid in HD
- Ginkgo biloba: Antiplatelet effect in fall-risk population; possible interaction with psychotropic medications; insufficient benefit to justify risk in HD
- Any dopaminergic supplement (Mucuna pruriens, L-DOPA precursors): Contraindicated — directly opposes the mechanism of VMAT2 inhibitors used for chorea management
Timeline Guide
A guide, not a prediction. HD has three parallel trajectories — motor, cognitive, and psychiatric — that progress at different rates in different patients.
Huntington's disease progression is measured by the UHDRS Total Functional Capacity (TFC) scale: Stage I (TFC 11–13) through Stage V (TFC 0). Median total disease duration from motor symptom onset is 15–20 years. The timeline below maps the hospice-relevant trajectory — most HD patients enter hospice at Stage IV–V. CAG repeat length, age of onset, and psychiatric disease severity all modify progression rate.[8]
YRS–
MOS
MOS
Premanifest & Early Manifest HD (Stage I–II)
- Genetic diagnosis may precede symptoms by years; subtle motor changes: slowed saccades, mild chorea, gait changes
- Psychiatric symptoms often dominant: depression, anxiety, irritability appearing before recognizable chorea
- Cognitive changes subtle but measurable on formal testing; working, driving, socially active
- Critical window: Advance directive completion, voice banking if dysarthria anticipated, surrogate designation, legacy work while fully cognitively capable[29]
- Genetic counseling for adult children; psychiatric treatment is the primary clinical need
MOS–
1 YR
1 YR
Mid-Stage HD (Stage III) — Palliative Integration Window
- Chorea prominent and functionally impairing; VMAT2 inhibitor or antipsychotic actively managing chorea
- Weight loss accelerating despite high-calorie diet; dysphagia developing — modified texture diet initiated
- Leaving employment; driving ended; requiring increasing assistance with ADLs
- Psychiatric symptoms ongoing requiring active management; fall risk increasing
- This is the most important palliative integration window and it is almost never used. Hospice enrollment as concurrent care with neurology is increasingly appropriate[16]
WKS–
MOS
MOS
Late-Stage HD (Stage IV–V) — Hospice Enrollment
- TFC ≤3; total dependence for ADLs; wheelchair-bound or bed-bound; severe dysphagia — PEG likely in place or under discussion
- Chorea may paradoxically decrease as rigidity and bradykinesia become dominant — the "burned out" phase; reassess VMAT2 inhibitor
- Cognitive impairment severe — cannot participate in care decisions; surrogate decision-making essential
- Aspiration pneumonia risk at maximum; recurrent pneumonia episodes accelerate decline[4]
- Focus: Comfort kit preparation, dysphagia management, psychiatric medication optimization, family genetic grief support
DAYS–
WKS
WKS
Pre-Active Dying — Terminal Phase
- Bed-bound; minimal oral intake even via PEG; sleeping most of day; recurrent aspiration; fever episodes
- Rigidity dominant — chorea largely absent; dystonic posturing may be severe and painful
- Medications transitioning to SQ/rectal routes; simplify regimen to core comfort agents
- Family teaching: what aspiration pneumonia death looks like; prepare for respiratory changes; have comfort medications drawn and labeled
HRS–
DAYS
DAYS
Final Hours
- Cheyne-Stokes or agonal breathing; mandibular breathing; mottling of knees and feet
- Unresponsive or minimally responsive; auditory awareness may persist — families should speak as though the patient hears
- Aspiration pneumonia may cause terminal respiratory distress — morphine and glycopyrrolate at bedside, drawn and labeled
- HD-specific: dystonic posturing may be distressing to family — reassure that positioning and benzodiazepines address this; the body's rigidity is not suffering[30]
Medications to Anticipate
HD requires two simultaneous medication frameworks: chorea/motor management via VMAT2 inhibitors and aggressive psychiatric treatment — plus caloric delivery as a medication priority.
🚨 Critical: VMAT2 Inhibitor Monitoring & Haloperidol Contraindication
Tetrabenazine requires CYP2D6 genotyping for doses >50 mg/day. Both tetrabenazine and deutetrabenazine require monthly depression and suicidality assessment. Haloperidol and other typical antipsychotics must NEVER be given to an HD patient — they cause severe motor worsening and can precipitate acute dyskinetic crisis. The safe antipsychotics in HD are quetiapine and clozapine.[13]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Deutetrabenazine | VMAT2 Inhibitor / Chorea | 6 mg BID, titrate by 6 mg/wk; max 48 mg/day | Preferred over tetrabenazine for tolerability. Requires monthly depression/suicidality assessment. At end-stage, reassess: has rigidity replaced chorea? If so, taper candidate.[14] |
| Tetrabenazine | VMAT2 Inhibitor / Chorea | 12.5 mg daily, titrate weekly | FDA-approved for HD chorea. CYP2D6 genotyping required >50 mg/day. Higher side effect burden than deutetrabenazine: depression, sedation, parkinsonism, suicidality. Contraindicated in untreated depression.[13] |
| Quetiapine | Atypical Antipsychotic / Chorea + Psychiatric | 25–100 mg BID-TID | Addresses chorea, irritability, psychosis, and sleep simultaneously. Preferred antipsychotic in HD. No CYP2D6 interaction with tetrabenazine at standard doses. Nighttime dosing aids sleep.[18] |
| Mirtazapine | NaSSA / Depression + Anorexia + Sleep | 15–30 mg PO/PEG at bedtime | Ideal end-stage HD antidepressant: antidepressant + appetite stimulation + sedation for sleep. Begin at enrollment if depression and weight loss co-exist. PEG-compatible.[17] |
| Clonazepam | Benzodiazepine / Chorea + Anxiety + Myoclonus | 0.5–1 mg PO BID-TID | Reduces chorea and anxiety simultaneously. Useful for myoclonus in late-stage HD. Sedating — fall risk. In end-stage, sedation is often acceptable for comfort goals.[31] |
| Morphine | Opioid / Pain + Dyspnea | 2.5–5 mg PO/SQ q4h | For pain from rigidity and dystonia in late-stage HD. For dyspnea from aspiration pneumonia. Titrate to comfort. Systemic route — not nebulized. |
| Citalopram/Sertraline | SSRI / Depression + Anxiety | Citalopram 10–20 mg daily; Sertraline 50–100 mg daily | Alternative to mirtazapine when weight/appetite are not primary concerns. Activating SSRIs (fluoxetine) may worsen irritability — avoid. Monitor for serotonin syndrome with VMAT2 inhibitors at high doses.[3] |
| Valproic Acid | Mood Stabilizer / Irritability + Myoclonus + Chorea | 250–500 mg BID | For severe irritability/aggression not responding to quetiapine. Also reduces myoclonus and chorea. Weight gain is a benefit in cachectic HD patients. Monitor hepatic function. ⚠ Caution: hepatotoxicity[32] |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. Essential in terminal phase for secretion management. |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN | Terminal agitation and catastrophic symptom management. Have in comfort kit drawn and labeled. Consider CSCI 10–30 mg/24h for refractory agitation. |
| Baclofen | Antispasmodic / Rigidity + Dystonia | 5–10 mg PO TID, titrate to 60–80 mg/day | For late-stage rigidity and dystonic posturing when chorea has subsided. Reduces painful spasticity. May improve positioning comfort. Sedation is common.[33] |
🌿 HD Symptom Management Decision Tree
Evidence-based · Hospice-adapted · Huntington's-specificSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Huntington's Disease
- Aspiration pneumonia crisis: Morphine 5 mg SQ + Glycopyrrolate 0.4 mg SQ — drawn and labeled at bedside for acute respiratory distress from aspiration
- Severe agitation / behavioral crisis: Midazolam 5 mg SQ — drawn and labeled; do NOT use haloperidol; if agitation is severe and refractory, quetiapine 50 mg PO/PEG or midazolam CSCI
- Dystonic pain crisis: Morphine 5 mg SQ + Lorazepam 1 mg SQ — for severe dystonic posturing causing pain in late-stage rigidity-dominant HD
- Seizure (especially juvenile HD): Midazolam 5 mg SQ/buccal or Lorazepam 2 mg SQ — drawn and labeled at bedside
Clinician Pointers
High-yield clinical pearls for the hospice team managing Huntington's disease. The things not in the textbook — learned at the bedside.
1
Depression in HD is biological — treat it with the same urgency as physical pain
It is not a natural response to a bad prognosis that should be "expected." It is driven by striatal neurodegeneration affecting the same dopaminergic and serotonergic pathways that psychiatric medications target. The patient with HD who has been untreated for depression because "who wouldn't be depressed?" has been failed clinically. Assess depression at enrollment with the same precision as chorea severity. Mirtazapine is the ideal agent in most end-stage HD patients.[3]
2
Chorea-driven weight loss is a clinical emergency
Caloric demand in HD far exceeds what families and clinicians typically expect. The patient who is eating "three meals a day" and losing weight in active chorea is not getting enough calories. 5,000–6,000 kcal/day in severe chorea is not an exaggeration. Assess weight at every visit. Calculate estimated caloric requirement. Supplement aggressively. The patient who enters end-stage HD cachectic has had inadequate nutritional support at prior stages.[22]
3
Haloperidol and typical antipsychotics must NEVER be given to an HD patient
They cause severe motor worsening and can precipitate acute dyskinetic crisis. If the family reports haloperidol given during an ER visit or by hospice on-call without HD familiarity, address it immediately. The safe antipsychotics in HD are quetiapine and clozapine. Write it on the allergy list. Say it to the family. Make it impossible to miss.[18]
4
Suicidality assessment belongs at every visit in cognitively intact HD
The patient in early or mid-stage HD with intact cognition and full awareness of their prognosis is at the highest suicide risk. Ask directly at every visit: "Some people with HD have thoughts about ending their life because of what's ahead. Have you had any thoughts like that?" This is not adequately managed by the antidepressant prescription alone — it requires direct questioning, documentation, and immediate escalation if active ideation is present.[21]
5
The chorea-to-rigidity transition changes everything
In end-stage HD, chorea often paradoxically decreases as bradykinesia and rigidity become dominant. This transition point requires complete medication reassessment: the VMAT2 inhibitor that was essential for chorea may now be adding side effect burden without benefit. Simultaneously, rigidity and dystonia emerge as the dominant comfort problems — requiring baclofen, benzodiazepines, and careful positioning. Recognize this transition. Act on it.[9]
6
Every meal is a potential aspiration event — never leave the patient unattended during meals
Dysphagia in HD is progressive and is the primary cause of death in 65–70% of HD patients. Swallowing assessment at enrollment. Modified texture diet per SLP. Small bites, chin-tuck technique, upright positioning for 30 minutes after meals. Educate every caregiver. Have the aspiration pneumonia crisis protocol at the bedside before the first episode.[4]
7
The genetic grief in the room is three generations deep
The patient dying of HD may have watched their parent die of it. Their adult children have a 50% chance of carrying the mutation. Some have been tested and know they carry it. Some have not been tested and live with uncertainty. Acknowledge all of these layers explicitly. Ask: "How is this affecting your children? Have they had the chance to talk to anyone about what this means for them?" You may be the first clinician who has asked.[34]
"The HD home is the hardest home in hospice. Not because the symptoms are unmanageable — they're hard but they're manageable. It's because everyone in the room is potentially living with a death sentence. The daughter who feeds her mother every meal may already know she carries the gene. When you walk in, you're caring for the whole family's future, not just the patient's present."
— Waldo, NP
Psychosocial & Spiritual Care
The genetic certainty, the inherited grief, the psychiatric overlay, and the three-generation impact that makes HD psychosocial care unlike any other diagnosis in hospice.
Huntington's disease is the only common fatal neurological disease in hospice where the family watching the patient die is also the family most at risk of developing the same disease. The patient's adult children have a 50% chance of having inherited the mutation. Some have been tested and know. Some have been tested and are negative and carry survivor guilt. Some have not been tested and live with uncertainty. Some have children of their own who are also potentially at risk. The grief in an HD home has three generations of layers. The hospice clinician who acknowledges all of them — explicitly and without rushing — is providing care that no other medical professional in the patient's life has offered.[34]
Psychiatric symptoms are the disease, not a reaction to the disease. Depression, irritability, and apathy in HD are caused by the striatal degeneration itself. They are not primarily a psychological response to a bad prognosis. The family that understands this is less likely to interpret psychiatric symptoms as personal failures or character changes. Explain the biology: "The same part of the brain that controls movement also regulates mood. As it is affected by HD, depression and irritability are direct symptoms of the disease, not choices or reactions."[3]
The Genetic Grief — Three Generations
The Patient Who Watched Their Parent Die
- Many HD patients were the caregiver for their parent with HD before developing it themselves
- They know exactly what is coming — they have a template for their own death built from watching someone they loved
- This prior experience is both a burden (they know every stage ahead) and a resource (they have already had many needed conversations)
- Acknowledge both dimensions: "You've seen this before in your family. That means you know things that can help us take better care of you — and it also means you're carrying memories that are very heavy."
The Children Who May Be Next
- ~50% risk of inheriting the mutation; some tested, some not; some in denial, some hyper-aware
- Tested positive carriers may be providing care while facing their own future — this is profoundly isolating
- Tested negative siblings may carry survivor guilt: "Why did I escape and my brother didn't?"
- Untested family members live in uncertainty — ask: "Have you had the chance to talk with a genetic counselor about what this means for you?"[7]
- Children of the patient who are minors cannot be tested — but their parents are living with the knowledge of risk
Depression & Suicidality
Depression in HD is biologically driven and affects 40–70% of patients. It often predates motor symptoms by years and is the most undertreated symptom in HD. Suicidality is a specific HD risk — 5–10% lifetime suicide rate, with highest risk during premanifest and early manifest stages when cognitive function is preserved. At hospice enrollment, assess both depression and suicidality at the first visit and at every subsequent visit. Use PHQ-9 or direct questioning: "Are you depressed?" — this single question has near-100% sensitivity in terminally ill populations.[21]
Clinical Pearl
"In HD, suicide risk peaks not when the patient is most disabled, but when they are most aware — early to mid-stage, with full cognitive understanding of what lies ahead. By the time the patient reaches end-stage hospice enrollment, the suicide risk has often shifted from the patient to the at-risk family members who are watching and imagining their own future. Screen the family too."
Spiritual Assessment
HD raises spiritual questions that are distinct from other terminal diagnoses: "Why did God give this to my family?" "Is it fair that my children may have this?" "I watched my mother die of this — am I being punished?" The genetic certainty of HD intensifies spiritual crisis. Use the FICA framework — but expect that the inherited nature of the disease will surface theological questions about fairness, punishment, and meaning that require chaplaincy expertise. Refer at enrollment, not at crisis.[35]
- 01Ask about the genetic burden explicitly: "How is the genetic side of this affecting your family? Have the children had the chance to talk with someone about what HD means for them?" You may be the first person to ask.
- 02Involve chaplaincy at enrollment: The spiritual dimensions of inherited fatal disease — guilt, punishment narratives, fairness — require expert spiritual care. Do not leave these conversations to chance.
- 03Legacy work is especially important in HD: The patient who is losing cognitive capacity has a closing window for legacy creation. Life review, video messages, written letters, memory books — these become the inheritance the family can keep. Start before the window closes.
- 04Connect to HDSA resources: The Huntington's Disease Society of America (HDSA) has social workers, support groups, and family resources specifically designed for HD families. They understand the genetic grief. Refer every family.[36]
"I've been in HD homes where the daughter is feeding her mother, and I can see in her hands the early chorea that hasn't been diagnosed yet. She knows. I know. We don't say it — not then, not in that moment. But later, when I ask her how she's doing, really doing, the dam breaks. She's been carrying this alone. Nobody in the medical system has asked about her. The hospice visit is for the patient, but in an HD home, the family is the patient too."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has Huntington's disease — a genetic brain condition that affects movement, thinking, and mood. You are watching something that is hard to watch. The involuntary movements, the difficulty swallowing, the personality changes — these are all caused by the disease, not by anything your person is choosing or can control. The medications the hospice team provides can manage many of these symptoms and keep your loved one more comfortable. You are not alone in this. We are here to help — not just with the patient, but with you and your family.
What You May See
- Involuntary movements (chorea): The arms, legs, face, and trunk move without control. This is the disease, not distress or pain. The medications manage this but cannot eliminate it. Protect from injury — pad bed rails, remove sharp objects nearby.
- Dramatic weight loss even when eating: The constant movement burns enormous calories. Your person may need 3–4 times the normal calorie intake. The nutrition plan is a medical priority — follow it carefully.
- Mood changes: Depression, irritability, anxiety, or apathy. These are caused by the same brain disease causing the movement disorder. They are not character changes. They are symptoms, and there are effective medications.[3]
- Difficulty swallowing: Choking or coughing with meals. Slowing down, taking small bites, and using the techniques your speech therapist showed you dramatically reduces risk. Never leave your person alone during meals.
- Increasing confusion and cognitive slowing: HD affects memory, planning, and judgment over time. Adjust expectations and simplify communication. Use short sentences and give time for responses.
- Falls: The involuntary movements combined with balance problems create significant fall risk. Modify the environment now — remove tripping hazards, install grab bars, clear pathways.
How You Can Help
- Never leave your person alone during meals: Sit beside them. Meals take a long time. The swallowing techniques (small bites, chin down, sitting upright for 30 minutes after) are safety measures, not suggestions.
- Offer high-calorie foods and drinks frequently: Small frequent high-calorie offerings rather than three large meals. The nutrition plan from the dietitian is a clinical document — follow it.
- Protect from injury from chorea: Pad bed rails, remove hard or sharp objects from reach, ensure wheelchair has appropriate supports, use non-spill cups and weighted utensils.
- Watch for mood changes and report them: Depression and irritability are treatable symptoms. If your person seems more withdrawn, tearful, or agitated than usual, tell the nurse — medication adjustments can help.
- Take care of yourself: HD caregiving is among the most demanding in hospice. You cannot sustain this alone. Use respite care. Call us when you need support — not just when the patient does. Ask about HDSA support groups.[36]
- If you are at risk for HD yourself: You deserve support too. The HDSA has resources for at-risk family members. Genetic counseling is available. You don't have to carry this alone.
📞 Call the nurse immediately if you see:
Choking during a meal that does not resolve with coughing — call 911 if airway is blocked; sudden fever with cough and rapid breathing (possible aspiration pneumonia); a fall resulting in head injury or inability to move a limb; statements about wanting to die or end their life — take this seriously and call immediately; a seizure (especially in juvenile HD) — note the time, protect the head, and call; sudden severe agitation or confusion that is different from their usual behavior; any new medication side effect — especially after starting or changing tetrabenazine or deutetrabenazine.
🙏 You are doing something extraordinarily hard. Caring for a person with Huntington's disease — especially when your family carries the genetic weight of this disease — is one of the most demanding things a person can do. Research shows that patients with engaged family caregivers have better symptom management and greater comfort. You are part of the medical team. Your presence matters. Your care matters. And you matter too.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Depression in HD is a biological symptom that requires the same urgency as physical pain. The striatum that is failing is the same structure that regulates mood — depression is as much a symptom of HD as chorea. Don't let anyone tell you the patient is "appropriately depressed given their diagnosis." That's clinical failure dressed as empathy. Mirtazapine at bedtime is your best single-drug choice in end-stage HD — antidepressant, appetite stimulant, sleep aid. One drug, three problems. Start it at enrollment.
- 02Chorea-driven weight loss is a clinical emergency that most families and clinicians underestimate. The patient eating three regular meals a day and still losing a pound a week is not getting enough calories. In severe chorea, 5,000 kcal/day is not an exaggeration — their body is running a marathon 24 hours a day. Weigh at every visit. Supplement aggressively. Scandishake between meals. If they're losing weight on three meals, add three high-calorie snacks. A cachectic HD patient at end-stage is telling you that nutritional support failed at earlier stages.
- 03Ask about suicidality directly at every visit in cognitively intact HD. This disease carries a 5–10% lifetime suicide risk, and the peak risk is not when they're most disabled — it's when they're most aware. The patient who knows their prognosis, who watched their parent die of this, who knows exactly what is coming — that patient is at risk. Ask: "Some people with HD have thoughts about ending their life. Have you had any thoughts like that?" The antidepressant does not eliminate suicidality in HD. Active monitoring does. Document the answer every single visit.
- 04Haloperidol is absolutely contraindicated in Huntington's disease. Write it in the chart. Put it on the allergy list. Say it to the family. The ER that gives haloperidol IM for HD behavioral agitation is causing serious harm — severe motor worsening, acute dyskinetic crisis, potentially irreversible. The safe antipsychotic is quetiapine. Know this before the crisis. Print it on a card and tape it to the fridge for the family to show to the ER. I've seen this go wrong. Don't let it happen to your patient.
- 05VMAT2 inhibitors — tetrabenazine and deutetrabenazine — require monthly depression monitoring. The medication that reduces chorea can also worsen depression and cause suicidality. This is not a theoretical warning. At every visit where the patient is on a VMAT2 inhibitor, ask about depression and suicidal thinking. If depression worsens after starting or increasing the dose, lower it or stop it. The chorea that the medication was managing may be less dangerous than the depression it's causing.
- 06The chorea-to-rigidity transition is the most important clinical turning point in end-stage HD, and most clinicians miss it. In late-stage HD, chorea often fades and rigidity takes over. The patient stops moving too much and starts not moving enough. Painful dystonic posturing replaces the dance-like chorea. At this point, the VMAT2 inhibitor may be doing nothing — stop it. Baclofen, benzodiazepines, and careful positioning become the new comfort priorities. Recognize the transition and act on it immediately.
- 07Have the aspiration conversation before the first aspiration event. Every HD family needs to hear: "Swallowing difficulty is the most serious complication of HD, and aspiration pneumonia is the most common cause of death. We're going to work hard on swallowing safety, but I want you to know what aspiration looks like so you're prepared: sudden fever, cough, rapid breathing, change in sputum color. When it happens — and it is a when, not an if — we have medications at the bedside to keep your person comfortable. You will not be alone." Say this early. Say it clearly. Families who are prepared handle the crisis better.
- 08HD is overwhelmingly a disease of European descent, with prevalence 5–10 per 100,000 in populations of European origin and significantly lower in East Asian and African populations. This means that in communities where HD is rare, the family's isolation is compounded — no one around them understands what they're going through. HDSA support groups and online communities become lifelines. For families from populations where HD is less recognized, the diagnostic journey may have been longer and more frustrating. Acknowledge the isolation. Connect them.
- 09HD caregivers are among the most burdened in all of hospice, and they're caring for someone who may have the same disease they're destined to develop. The caregiver who is also a gene carrier is doing something that defies description — they're rehearsing their own death while managing their parent's. Watch them. Ask them how they're sleeping. Ask them who's supporting them. Refer them to the HDSA social worker. Refer them to the hospice social worker. Refer them to the chaplain. They will not ask for help. You have to offer it — and then offer it again.
- 10In every HD home, there is a person dying, a parent who died before them, and a child who may die after them. Three generations. One mutation. The hospice clinician who walks in and sees all three — not just the patient in the bed — is providing care that the medical system has failed to offer at every prior stage. You cannot cure Huntington's disease. You cannot undo the genetics. But you can walk into that home and be the first person who acknowledges all of it — the past, the present, and the fear of the future — and say: "I see all of this. I'm here for all of you." That's the job. That's the whole job.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Rawlins MD, Wexler NS, Wexler AR, et al. The prevalence of Huntington's disease. Neuroepidemiology. 2016;46(2):144–153.
2
MacDonald ME, Ambrose CM, Duyao MP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971–983.
3
Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310–314.
4
Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first-degree relatives. J Med Genet. 1992;29(12):911–914.
5
Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–216.
6
Walker FO. Huntington's disease. Lancet. 2007;369(9557):218–228.
7
MacLeod R, Tibben A, De Wert G, et al. Recommendations for the predictive genetic test in Huntington's disease. Clin Genet. 2013;83(3):221–231.
8
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136–142.
9
Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.
10
Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011;25(1):1–14.
11
Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet. 1993;4(4):387–392.
12
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington's disease. N Engl J Med. 2019;380(24):2307–2316.
13
Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366–372.
14
Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial (FIRST-HD). JAMA. 2016;316(1):40–50.
15
Hamilton A, Heemskerk AW, Loucas M, et al. Oral feeding in Huntington's disease: a systematic review. J Huntingtons Dis. 2012;1(1):33–46.
16
Veenhuizen RB, Kootstra B, Vink W, et al. Coordinated multidisciplinary care for ambulatory Huntington's disease patients. J Multidiscip Healthc. 2011;4:189–195.
17
Rosenblatt A. Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci. 2007;9(2):191–197.
18
Coppen EM, Roos RAC. Current pharmacological approaches to reduce chorea in Huntington's disease. Drugs. 2017;77(1):29–46.
19
de Tommaso M, Serpino C, Difruscolo O, et al. Dysphagia in Huntington's disease: correlation with clinical features. Eur Neurol. 2015;74(1-2):49–53.
20
Finucane TE, Christmas C, Travis K. Tube feeding in patients with advanced dementia: a review of the evidence. JAMA. 1999;282(14):1365–1370.
21
Hubers AA, Reedeker N, Giltay EJ, et al. Suicidality in Huntington's disease. J Affect Disord. 2012;136(3):550–557.
22
Trejo A, Tarrats RM, Alonso ME, et al. Assessment of the nutrition status of patients with Huntington's disease. Nutrition. 2004;20(2):192–196.
23
Bradt J, Dileo C, Magill L, et al. Music interventions for improving psychological and physical outcomes in people with cancer. Cochrane Database Syst Rev. 2016;(8):CD006911.
24
Power E, Anderson A, Togher L. Pragmatic communication in Huntington's disease. J Neurolinguistics. 2011;24(5):532–544.
25
McGarry A, McDermott M, Kieburtz K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2CARE). Neurology. 2017;88(2):152–159.
26
Goodman AO, Rogers L, Pilsworth S, et al. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep. 2011;11(2):211–217.
27
Hersch SM, Schifitto G, Oakes D, et al. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89(6):594–601.
28
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777–1798.
29
Etchegary H. Psychological aspects of predictive genetic-test decisions: lessons learned from Huntington disease. Curr Genet Med Rep. 2013;1(1):55–63.
30
Nance MA. Comprehensive care in Huntington's disease: a physician's perspective. Brain Res Bull. 2007;72(2-3):175–178.
31
Jankovic J, Roos RAC. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord. 2014;29(11):1414–1418.
32
Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients. Mov Disord. 2006;21(10):1746–1751.
33
Thompson JA, Cruickshank TM, Penailillo LE, et al. The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease. Eur J Neurol. 2013;20(9):1325–1329.
34
Aubeeluck AV, Buchanan H, Stupple EJ. 'All the burden on all the carers': exploring quality of life with family caregivers of Huntington's disease patients. Qual Life Res. 2012;21(8):1425–1435.
35
Puchalski CM, Vitillo R, Hull SK, et al. Improving the spiritual dimension of whole person care: reaching national and international consensus. J Palliat Med. 2014;17(6):642–656.
36
Huntington's Disease Society of America. HDSA Family Guide to Huntington's Disease. hdsa.org. 2023.
37
Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369–384.
38
Landwehrmeyer GB, Fitzer-Attas CJ, Giuliano JD, et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington's disease. Mov Disord Clin Pract. 2017;4(2):212–224.
39
Pringsheim T, Wiltshire K, Day L, et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–1091.
40
Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874–880.
41
van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–1418.
42
Anderson KE, van Duijn E, Huntington Study Group. Clinical management of neuropsychiatric symptoms of Huntington disease: expert-based consensus guidelines. J Huntingtons Dis. 2023;12(1):3–23.
43
Aziz NA, van der Marck MA, Pijl H, et al. Weight loss in neurodegenerative disorders. J Neurol. 2008;255(12):1872–1880.
44
Tibben A. Predictive testing for Huntington's disease. Brain Res Bull. 2007;72(2-3):165–171.
45
Zarowitz BJ, O'Shea T, Nance M. Clinical, demographic, and pharmacologic features of nursing home residents with Huntington's disease. J Am Med Dir Assoc. 2014;15(6):423–428.
46
Moskowitz CB, Marder K. Palliative care for people with late-stage Huntington's disease. Neurol Clin. 2001;19(4):849–865.
47
Carlozzi NE, Tulsky DS, Chiaravalloti ND, et al. HDQLIFE: development and assessment of health-related quality of life in Huntington disease. Qual Life Res. 2016;25(10):2441–2455.
48
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.